



ACTIVE PHARMACEUTICAL INGREDIENTS

PRODUCT CATALOGUE SEPTEMBER 2020

APIs - UNDER DEVELOPMENT	THERAPEUTIC AREA	STATUS
Bilastine	Anti-histaminic	Lab validation
Brivaracetam	Antiepileptic	Lab validation
Diroximel Fumarate	Immunosuppressant	Lab validation
Edoxaban	Anti-coagulant	Lab validation
Elagolix Sodium	GnRh antagonist	Lab Validation
Empagliflozin	Anti-diabetic	Lab development
Eslicarbazepine acetate	Anti-convulsant	Lab development
Hydralazine	Antihypertensive	Lab development
Labetalol	Anti-hypertensive	Lab development
Lasmiditan	Anti-migraine	Lab development
Nebivolol HCl	Antihypertensive	Lab development
Patiromer	Anti-hyperkalemic	Lab development
Tafamidis	Transthyretin stabilizer	Lab development
Umifenovir	Anti-viral	Lab development
Verapamil	Anti-hypertensive	Lab validation

Items covered by valid patents are not offered or supplied for commercial sale.

The patent position should be verified by the buyer.

***Products under patent are available for R&D use pursuant to 35 U.S.C. 271(e)(1) or Section 107A of the Indian Patent Act, 1970. ***

Product filings till September 2020

*Regulatory Filing planned



ACTIVE PHARMACEUTICAL INGREDIENTS

PRODUCT CATALOGUE SEPTEMBER 2020

APIs - VALIDATED		THERAPEUTIC AREA	US	CANADA	EUROPE	CEP	JAPAN	BRAZIL	SOUTH KOREA	RUSSIA
A	Adapalene	Anti-acne								
	Alogliptin Benzoate	Anti-diabetic								
	Amiodarone HCl	Anti-arrhythmic								
	Apixaban	Anti-coagulant								
	Apremilast	Immunomodulator								
	Aprepitant	Anti-emetic					*			
	Arformoterol Tartrate	Respiratory agent								
	Atomoxetine	Anti-psychotic								
	Atovaquone	Anti-parasitic								
	Azelaic Acid	Anti-acne								
Azelnidipine	Anti-hypertensive									
Azilsartan (Base)	Anti-hypertensive									
B	Bosentan	Anti-hypertensive								
	Bupropion HCl	Anti-depressant								
	Butenafine HCl	Anti-fungal								
C	Canagliflozin Hemihydrate	Anti-diabetic								
	Cilazapril	Anti-hypertensive								
	Cilostazol	Anti-platelet								
	Colesevelam	Lipid-modifying agent								*
Colistimethate Sodium	Antibiotic									
D	Dabigatran Etxilate Mesylate	Anti-coagulant								
	Dapagliflozin Amorphous	Anti-diabetic								
	Deferasirox	Iron chelator								
	Deoxycholic Acid	Cytolytic								
	Desloratadine	Anti-histaminic								
	Dimethyl Fumarate	Immunosuppressant								
	Dipyridamole	Anti-platelet								
	Dronedarone	Anti-arrhythmic								
E	Efinaconazole	Anti-fungal								
	Esomeprazole Mg (Dihydrate)	Anti-ulcerative								
	Esomeprazole Mg (Trihydrate)	Anti-ulcerative								
	Esomeprazole Sodium	Anti-ulcerative								

Items covered by valid patents are not offered or supplied for commercial sale.
The patent position should be verified by the buyer.

***Products under patent are available for R&D use pursuant to 35 U.S.C. 271(e)(1) or Section 107A of the Indian Patent Act, 1970. ***

Product filings till September 2020

*Regulatory Filing planned



ACTIVE PHARMACEUTICAL INGREDIENTS

PRODUCT CATALOGUE SEPTEMBER 2020

APIs - VALIDATED	THERAPEUTIC AREA	US	CANADA	EUROPE	CEP	JAPAN	BRAZIL	SOUTH KOREA	RUSSIA
Eszopiclone	Hypnotic								
Etoricoxib	Analgesic								
Ezetimibe	Anti-hyperlipidemic								
F Favipiravir	Anti-viral								
Fingolimod HCl	Immunosuppressant								
Fluconazole	Anti-fungal								
Fosaprepitant Dimeglumine	Anti-emetic								
Frovatriptan Succinate	Anti-migraine								
G Gabapentin Enacarbil	Antiepileptic								
Garenoxacin	Antibiotic								
Glimepiride	Anti-diabetic								
I Imiquimod	Immunomodulator								
Iron Sucrose	Hematinic								
Ivacaftor	Respiratory agent								
L Lacosamide	Antiepileptic								
Lercanidipine HCl	Anti-hypertensive								
Levocetirizine DiHCl	Anti-histaminic								
Lifitegrast	Ophthalmologic agent								
Linagliptin	Anti-diabetic								
Lithium Carbonate	Anti-manic								
Lomitapide Mesylate	Anti-hyperlipidemic								
Lornoxicam	Analgesic								
Luliconazole	Anti-fungal								
Lurasidone	Anti-psychotic								
M Milnacipran HCl	Anti-depressant								
Mirabegron	Urinary anti-spasmodic								
Moexipril HCl	Anti-hypertensive								
N Nintedanib Esylate	Antineoplastic & Immunomodulator								
O Olmesartan Medoxomil	Anti-hypertensive								
Olopatadine HCl	Ophthalmologic agent								
Omeprazole	Anti-ulcerative								
Oxcarbazepine	Anti-convulsant								

Items covered by valid patents are not offered or supplied for commercial sale.

The patent position should be verified by the buyer.

***Products under patent are available for R&D use pursuant to 35 U.S.C. 271(e)(1) or Section 107A of the Indian Patent Act, 1970. ***

Product filings till September 2020

*Regulatory Filing planned



ACTIVE PHARMACEUTICAL INGREDIENTS

PRODUCT CATALOGUE SEPTEMBER 2020

APIs - VALIDATED		THERAPEUTIC AREA	US	CANADA	EUROPE	CEP	JAPAN	BRAZIL	SOUTH KOREA	RUSSIA	
P	Perindopril Arginine	Anti-hypertensive									
	Perindopril Erbumine	Anti-hypertensive									
	Pirfenidone	Anti-fibrotic agent									
	Prasugrel Base	Anti-platelet									
	Prasugrel HCl	Anti-platelet									
	Proguanil HCl	Anti-malarial									
R	Ranolazine	Anti-anginal									
	Rasagiline Mesylate	Anti-parkinsonian									
	Rasagiline Tartrate	Anti-parkinsonian									
	Riluzole	Neuro-protective agent									
	Rivaroxaban	Anti-coagulant									
	Rizatriptan Benzoate	Anti-migraine									
	Roflumilast	Respiratory agent									
	Ropinirole HCl	Anti-parkinsonian									
	Rosuvastatin Calcium	Anti-hyperlipidemic									
	Rufinamide	Anti-convulsant									
	S	Saxagliptin Monohydrate	Anti-diabetic								
		Sertaconazole Nitrate	Anti-fungal								
		Solifenacin Succinate	Urinary anti-spasmodic								
Solriamfetol		Anti-narcoleptic									
Sucralfate		Anti-ulcerative									
T	Tadalafil	Urologic agent									
	Tavaborole	Anti-fungal									
	Telmisartan	Anti-hypertensive									
	Teneligliptin	Anti-diabetic									
	Terbinafine HCl	Anti-fungal									
	Teriflunomide	Immunomodulator									
	Ticagrelor	Anti-platelet									
	Tofacitinib Citrate	Immunomodulator									
	Topiramate	Antiepileptic									
	Trandolapril	Anti-hypertensive									
	Trospium Cl	Urinary anti-spasmodic									

Items covered by valid patents are not offered or supplied for commercial sale.
The patent position should be verified by the buyer.

***Products under patent are available for R&D use pursuant to 35 U.S.C. 271(e)(1) or Section 107A of the Indian Patent Act, 1970. ***

Product filings till September 2020

*Regulatory Filing planned



ACTIVE PHARMACEUTICAL INGREDIENTS

PRODUCT CATALOGUE SEPTEMBER 2020

APIs - VALIDATED	THERAPEUTIC AREA	US	CANADA	EUROPE	CEP	JAPAN	BRAZIL	SOUTH KOREA	RUSSIA
V Vilazodone HCl	Anti-depressant								
Vildagliptin	Anti-diabetic								
Voriconazole	Anti-fungal								
Z Zolmitriptan	Anti-migraine								
Zolpidem Tartrate	Hypnotic								
Zonisamide	Antiepileptic								



Facilities



Regulatory certifications



Markets

Facilities	Regulatory certifications	Markets
Ankleshwar	US FDA, MHRA, KFDA, PMDA, EMEA, COFEPRIS, Health CANADA	US, EU, JP, Emerging Markets
Dahej	US FDA, KFDA, PMDA, EDQM	US, EU, JP, Emerging Markets
Mohol	US FDA, Local FDA	India, Emerging Markets
Kurkumbh	Local FDA	India

Items covered by valid patents are not offered or supplied for commercial sale.

The patent position should be verified by the buyer.

***Products under patent are available for R&D use pursuant to 35 U.S.C. 271(e)(1) or Section 107A of the Indian Patent Act, 1970. ***

Product filings till September 2020

*Regulatory Filing planned